Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy?
CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Friday, December 26, according to its daily fund disclosures. The firm added to its position in gene-editing company CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results